Your DNA results are in — and they're 100% the property of a pharmaceutical manufacturer. It was announced today that 23andMe, the consumer-genomics company that sold take-home DNA kits, will be bought out of bankruptcy by the American biotech company Regeneron Pharmaceuticals. According to press releases, Regeneron is to pay $256 million in cash to acquire "substantially all" of 23andMe's assets, including its massive biobank of around 15 million customer genetic samples and data — meaning that the genetic information of millions is now in the hands of a drugmaker seeking to mine it to make new therapies. Said samples […]